Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

101.42 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis Ag ADR

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Drug Maker Novartis Stock Shows Rising Relative Strength
Novartis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the preferred 80-plus score. 
Via Investor's Business Daily
Earnings Preview For Novartis
Via Benzinga
MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022
MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments for... 
Via Benzinga
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 to 2030. 
Via Benzinga
S&P Makes Weekly Advance As Inflation Reaches Lowest Level Since March 2021; Amazon, Microsoft, Alphabet And Major Banks Lead Market Optimism
The S&P 500 is closing the week in the green in light of positive inflation data. The index was 2.48% higher on the week ahead of the market close Friday. Other major market indexes also showed an... 
Via Benzinga
(NVS) - Analyzing Novartis's Short Interest
Via Benzinga
Eli Lilly Unveils A Nearly $2 Billion Deal To Leap Ahead In Weight Loss
The company is hoping to curb the lean muscle mass loss tied to weight-loss drugs. 
Via Investor's Business Daily
The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?
An overweight world is hungry for new treatments. For now, two companies own the market. 
Via Investor's Business Daily
3 Penny Stocks to Catapult You Into the Millionaires’ Club
These penny stocks can deliver tremendous upside from their depressed range. Wall Street analysts can back it up! 
Via InvestorPlace
Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ: WINT) Is Helping Change That
Windtree Therapeutics, Inc. (NASDAQ: WINT), a biotechnology company treating late-stage acute cardiovascular disorders, is advancing its first-in-class drug for serious heart conditions. 
Via Benzinga
3 Biotech Stocks That AI is Loving in July
As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential. 
Via InvestorPlace
Why Are BeiGene Shares Trading Lower Today
BeiGene Limited (NASDAQ: BGNE) shares are trading lower after the company mutually agreed to  
Via Benzinga
US Court Issues Negative Decision On Novartis' Heart-Failure Drug Patent
Swiss pharma giant Novartis AG (NYSE: NVS)  
Via Benzinga
Why Novartis Stock Slipped on Friday
A major company product lost a key legal protection. 
Via The Motley Fool
Bausch + Lomb Expands OTC Eye Care Portfolio, Acquires JNJ's Blink
Bausch + Lomb Corporation (NYSE: BLCO) has acquired Johnson & Johnson's (NYSE: JNJ) eye and contact lens drops brand Blink for $106.5 million to bolster its position in over-the-counter (OTC)... 
Via Benzinga
Novartis Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire
Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis. 
Via Investor's Business Daily
Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment
Biogen Inc (NASDAQ: BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting  
Via Benzinga
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
Via Talk Markets
Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday
The biotech's board is exploring strategic alternatives to boost shareholder value. 
Via The Motley Fool
Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories
New York Post 
Via Benzinga
Bausch + Lomb Poised To Boost Presence In Growing Market With Potential $1.75B Drug Acquisition Deal From Novartis
Bausch + Lomb Corporation (NYSE: BLCO) has agreed to acquire 'front of eye' ophthalmology assets for $1.75 billion in upfront cash, plus additional milestone payments from Novartis AG (NYSE: 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Amgen Out, Rio Tinto In As Morgan Stanley Shuffles Dividend Deck
Via Benzinga
7 Top Growth Stocks to Watch for H2 2023
Many growth stocks still haven't completely recovered from their 2022 losses, so they have plenty of opportunities to do so in H2 2023. 
Via InvestorPlace
What Is CRISPR And Why Should Your Portfolio Care?
CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player. 
Via Talk Markets
Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst
Raymond James has initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN) with an Outperform rating and a  
Via Benzinga
Terns Pharma Has 35% Upside According To This Analyst, NASH Asset To Drive Valuation
Mizuho initiated coverage on Terns Pharmaceuticals Inc (NASDAQ: TERN) with a Buying rating and price target of $16,  
Via Benzinga
Why Shares of Vera Therapeutics Jumped Tuesday
The company announced early phase 2 trials information regarding its lead therapy. 
Via The Motley Fool
Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions
An immunology drug of the Swiss pharmaceutical giant was approved for yet another indication in the European Union. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.